PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Background Individual participant data meta-analyses of postoperative chemotherapy have
shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …

Purpose Several recent trials have shown a significant overall survival (OS) benefit from
postoperative cisplatin-based chemotherapy in patients with non–small-cell lung cancer …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Background Whether adjuvant chemotherapy improves survival of patients with non-small-
cell lung cancer (NSCLC) is not known. We aimed to compare the effect of adjuvant …

Background We undertook to determine whether adjuvant vinorelbine plus cisplatin
prolongs overall survival among patients with completely resected early-stage non–small …

BACKGROUND: Many randomised controlled trials have investigated the effect of adjuvant
chemotherapy in operable non-small-cell lung cancer. We undertook two comprehensive …

Lung cancer represents the leading cause of cancer mortality worldwide, accounting for 1.2
million deaths each year. Improving survival in lung cancer is a major challenge for modern …